Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MORDECAI N KLEIN

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1881629541
CMS profile
39469
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$571.40

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $571.40 13

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Abbott Laboratories $299.73 8
ABIOMED $146.20 1
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $110.32 3
Amgen Inc. $15.15 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MORDECAI N KLEIN

NPI 1881629541 · CMS profile ID 39469

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881629541?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MORDECAI N KLEIN, NPI 1881629541, CMS profile ID 39469. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881629541?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MORDECAI N KLEIN, NPI 1881629541, CMS profile ID 39469. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881629541?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MORDECAI N KLEIN, NPI 1881629541, CMS profile ID 39469, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881629541?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $571.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $12.9412/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664621085 CMS
Abbott Laboratories $41.2511/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664576329 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $14.0110/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625188715 CMS
Abbott Laboratories $8.0010/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664551647 CMS
Amgen Inc. $15.1510/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662801881 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $89.6409/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625188713 CMS
Abbott Laboratories $22.2309/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664508807 CMS
ABIOMED $146.2009/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676719619 CMS
Abbott Laboratories $93.7007/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664521803 CMS
Abbott Laboratories $12.9207/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664520023 CMS
Abbott Laboratories $55.5105/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664538341 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $6.6705/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625188717 CMS
Abbott Laboratories $53.1802/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664583213 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $571.40 13
PY2020 $460.10 12
PY2021 $670.69 18
PY2022 $235.49 15
PY2023 $343.31 9
PY2024 $14.87 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $21,937.23 3
PY2024 Recipient $157,914.00 1
PY2024 Principal investigator $15,059.92 62
PY2023 Principal investigator $115,948.65 231
PY2022 Principal investigator $37,811.35 326
PY2021 Principal investigator $24,001.00 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

326 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088583
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088601
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 12/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,750.00 12/02/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,820.00 12/02/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 12/02/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $750.00 12/02/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $275.00 12/02/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088523
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088853
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088899
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910088927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910090097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910090107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910090115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910090125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088652
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910089229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910090073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910090081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9.45 10/17/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910088733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.90 10/17/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910090089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085390
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085406
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085483
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085078
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085257
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085263
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085594
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085654
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910085220
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085284
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085298
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085509
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085517
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085527
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910085535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088488
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088497
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $972.00 06/01/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088269
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088311
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088319
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 05/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910088049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/29/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910088243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,533.00 04/04/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910086809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910086819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910086827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910086931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910086941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910086951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910086959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910086969
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910086979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086999
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 03/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,138.00 03/02/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087577
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087587
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087607
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087773
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 02/28/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 02/15/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910087437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087464
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087510
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $600.00 01/17/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 01/17/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 01/17/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 01/17/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 01/17/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910087567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,580.00 01/05/2022 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910086755